Abstract YO34
Case summary
Background
Alteration in Urinary phosphate levels has been considered to be a paraneoplastic syndrome. This case report sheds light on a rare endocrinological cause of limb weakness.
Case details
A 31 year old female, a known case of pleomorphic leiomyosarcoma post surgery, post adjuvant chemotherapy with recently diagnosed parenchymal and pleural deposits presented with weakness in legs since the past 3 days, abnormal movements involving both the arms since the past 1 day and altered sensorium since the past 2 days. There was no history of symptoms of raised intracranial tension or metastatic spinal cord compression. Examination revealed reduced power in both the upper and lower limbs with downgoing flexors. Further investigation revealed reduced levels of serum phosphate, serum calcium and transaminiitis. Based upon recent reports available with the patient, vitamin D levels were found to be low whereas Intact PTH was found to be normal. A diagnosis of tumor induced osteomalacia versus Pazopanib induced fanconi’s syndrome was considered. She was started on oral phosphate supplements and vitamin D.
Conclusion
Tumor induced osteomalacia needs to be recognized as a reversible causes of quadriparesis in the advanced cancer population with mesenchymal tumours. The diagnosis was made in the Palliative medicine ward in the absence of 24 hour urinary phosphate levels or serum FGF levels.
Laboratory parameters | 24-01-2019 | 25-01-2019 |
Total Calcium | 1.9 | 1.5 |
Serum Urea | 20 | 17 |
Serum Creatinine | 0.5 | 0.4 |
Serum Uric Acid | 3.5 | |
Serum Sodium | 134 | |
Serum Potassium | 3.03 | |
Serum Chloride | 105.8 | |
Serum PTH | 71.90 | |
Serum Vitamin D3 | 12.26 | |
Total leucocyte count | 1070 | 900 |
Serum Haemoglobin | 13.2 | 9.7 |
QTc interval (corrected) | ||
Bazette's | 0.5 | 0.47 |
Frederica's | 0.49 | 0.46 |
Framingham | 0.52 | 0.46 |
Hodges | 0.52 | 0.45 |
Clinical trial identification
Editorial acknowledgement
Resources from the same session
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract